Independent reports described multiple early-stage inhibitor programs across oncology targets, including a novel PGK1 inhibitor showing dose-dependent suppression in pancreatic cancer assays. The PGK1 compound potently inhibited PGK1 in vitro and reduced glycolytic activity in a direct PGK1 glycolysis-related assay, supporting the idea that glycolysis blockade may impair tumor-relevant metabolism in pancreatic cancer models. Separately, other preclinical inhibitor disclosures in the provided set point to ongoing chemistry development across cancer targets, reflecting continued pipeline construction even before clinical translation. For biotech teams, the key next steps are confirmation of selectivity, in vivo efficacy, and toxicity profiling as these programs move from model systems toward candidate nomination for IND-enabling work.